Ideaya, Broad Institute partner on CRISPR synthetic lethality library

By The Science Advisory Board staff writers

October 22, 2020 -- Ideaya Biosciences has entered into a target and biomarker discovery partnership with the Sellers Laboratory at the Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard. The partners will utilize a CRISPR paralog screening platform to evaluate functionally redundant paralogous genes across ovarian cancer subtypes.

The team, led by Dr. William Sellers, core institute member of the Broad Institute, hopes to generate novel synthetic lethality-based target and biomarker discoveries. They will use Ideaya's decipher dual CRISPR synthetic lethality platform, which was developed in conjunction with the University of California, San Diego.

The platform contains a library focused on DNA damage repair targets across various tumor suppressor genes and oncogenes. This allows researchers to evaluate approximately 50,000 independent gene knockout combinations of DNA damage response (DDR) pathway-related drug targets across known tumor suppressor genes.

In addition, Ideaya and Broad will collaborate to evaluate paralog CRISPR knockdown in selected cell lines in conjunction with pharmacological inhibition of Poly (ADP-ribose) glycohydrolase (PARG) to inform patient selection and combination strategies in both ovarian and breast cancer.

Ideaya has also become a member of the Cancer Dependency Map (DepMap) consortium led by Broad Institute.

Ideaya, Pfizer expand clinical collaboration
Ideaya Biosciences has expanded its clinical trial collaboration and supply agreement with Pfizer for the combination study of IDE196, a protein kinase...
New CRISPR-repressor system improves efficiency of gene therapies
Researchers have developed a CRISPR-based system that can simultaneously provide transcriptional control and gene editing on demand to improve the efficacy...
Ideaya and GSK partner on synthetic lethality programs
Ideaya Biosciences and GlaxoSmithKline (GSK) have formed a strategic partnership in the emerging oncology field of synthetic lethality.

Copyright © 2020 scienceboard.net


Conferences
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter